Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children.
about
Co-infection subverts mucosal immunity in the upper respiratory tractCorrelates of Protection for M Protein-Based Vaccines against Group A StreptococcusThe potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experiencePneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children.Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccinesEvidence of early B-cell dysregulation in simian immunodeficiency virus infection: rapid depletion of naïve and memory B-cell subsets with delayed reconstitution of the naïve B-cell population.Phase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infantsUse of opsonophagocytosis for serological evaluation of pneumococcal vaccines.Older adults have a low capacity to opsonize pneumococci due to low IgM antibody response to pneumococcal vaccinationsResponse to Pneumococcal Polysaccharide Vaccination in Newly Diagnosed HIV-Positive IndividualsSafety, immunogenicity and efficacy of pneumococcal conjugate vaccine in HIV-infected individuals.Humoral immune responses to Plasmodium falciparum among HIV-1-infected Kenyan adultsAntiretroviral therapy for children: challenges and opportunities.Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.Immunogenicity following the first and second doses of 7-valent pneumococcal conjugate vaccine in HIV-infected and -uninfected infants.The Saudi Thoracic Society pneumococcal vaccination guidelines-2016.Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency.Population-based impact of routine infant immunization with pneumococcal conjugate vaccine in the USA.Vaccines to prevent pneumonia and improve child survival.Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.Immunogenicity following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine.Glycoconjugate vaccines.Pneumococcal immunization in immunocompromised hosts: where do we stand?PCVs in individuals at increased risk of pneumococcal disease: a literature review.Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption.Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
P2860
Q27002952-3C874957-DC39-4374-893D-671F899AEF8EQ27009175-361C2B5A-9CC4-4A61-B60F-4A7BC931D6E4Q28088507-31CFC5B7-86D8-4B78-996A-A77EC5765A4CQ30235055-A5AE3472-300C-4CD8-A098-7DFC12D3B232Q33613509-626A7AAC-5490-48C7-AF5B-CFCD4E3B595AQ33648998-FBE7159D-8665-439F-BF36-70120A67D321Q33844571-EE3EB261-7A92-4E2A-BD71-0FE4345BE04AQ33988269-E31996DB-0829-4845-AA96-00A164507FD7Q34429349-F8BCD702-9C50-494B-85FE-4BD70AE2AD24Q34484625-50CB7DE2-3811-4564-955F-7EBAC50FD85DQ35511216-5DD648B3-9143-4A39-8ADD-BCA473BAF94FQ36009704-60455903-5877-4DF7-B44A-9A1A4F627054Q36123104-95A1778E-C75D-40C5-B3D4-15A8BA084E94Q36806770-85A3271B-DD99-4A06-9F67-11C6EDE903DAQ36809473-8887CD9E-108E-42A7-B937-BB74F6366587Q36822003-D4A157C8-9499-4529-A8FC-C60234B40862Q36861485-1728D73E-196C-4DE1-BCE6-6B7350D9084DQ36953488-CC051669-68FF-40EA-A822-8597EECC1795Q37077655-BE7747C6-338A-4EAC-9FFD-3943AE6BF16EQ37108802-3BDD12BA-D159-415B-9F19-F09509292821Q37302272-D72F30B5-8F85-46D9-96C3-92B851ACC9ACQ37325678-453B4C2A-F995-45F1-A610-8FE0403AE521Q38044755-4A370D26-EFA5-495E-8576-523B1C16D9B1Q38168902-EAF3CCEB-F9AB-40B7-B468-8773AC854905Q38530267-07795DAB-AF9E-44EB-9B02-ADC7B4F2E19BQ39657425-39FD7E30-3127-41AD-91FD-7245DEB5AD1BQ45754377-C93A6B75-D828-46C3-A879-52C5E0898FF3
P2860
Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Quantitative and qualitative a ...... ected and uninfected children.
@en
Quantitative and qualitative a ...... ected and uninfected children.
@nl
type
label
Quantitative and qualitative a ...... ected and uninfected children.
@en
Quantitative and qualitative a ...... ected and uninfected children.
@nl
prefLabel
Quantitative and qualitative a ...... ected and uninfected children.
@en
Quantitative and qualitative a ...... ected and uninfected children.
@nl
P50
P1476
Quantitative and qualitative a ...... ected and uninfected children.
@en
P2093
Helena Käyhty
P304
P356
10.1097/01.INF.0000160942.84169.14
P577
2005-05-01T00:00:00Z